This study is currently not recruiting participants.

A RANDOMIZED PHASE II EVALUATION OF SINGLE-AGENT BEVACIZUMAB (IND #7921) (NSC #704865) AND COMBINATION BEVACIZUMAB WITH FOSBRETABULIN TROMETHAMINE (CA4P) (NSC #752293) IN THE TREATMENT OF RECURRENT OR PERSISTENT EPITHELIAL OVARIAN FALLOPIAN TUBE OR PRIMA

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The main purpose of this study is to compare the effectiveness of the drug bevacizumab to the combination of bevacizumab and the drug fosbretabulin tromethamine (CA4P) in treating cancer and to determine the types and severity of side effects caused by tr

Description

The main purpose of this study is to compare the effectiveness of the drug bevacizumab to the combination of bevacizumab and the drug fosbretabulin tromethamine (CA4P) in treating cancer and to determine the types and severity of side effects caused by tr

Details
Condition Ovarian Cancer, Fallopian Tube Cancer
Age 18years - 100years
Clinical Study IdentifierTX2544
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.